Semaglutide vs Tirzepatide: A Comparative Analysis

Two of the most researched metabolic peptides in recent years are semaglutide (GLP-1 agonist) and tirzepatide (GLP-1/GIP dual agonist). This analysis examines their structural differences, receptor binding profiles, and research outcomes. ## Receptor Binding Profiles Semaglutide binds exclusively to GLP-1 receptors, while tirzepatide targets both GLP-1 and GIP receptors, giving it a dual mechanism advantage. ## Research Outcomes Studies suggest tirzepatide may produce greater metabolic effects due to its dual agonist nature, though semaglutide has a longer research track record.